FDA approves Braftovi + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer (CRC) after prior therapy.- Pfizer
Related news and insights
Sumitomo Dainippon Pharma Oncology announced that the phase III CanStem303C study evaluating the efficacy and safety of investigational agent BBI 608 (napabucasin) when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS).
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Equidacent (bevacizumab biosimilar), from Centus Biotherapeutics Europe, intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Results from the phase II DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited and AstraZeneca’s Enhurtu (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful activity in patients with HER2 positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.